FDA Seeks Public Feedback on Cybersecurity and Safety Risks of Autonomous and Remote Teleoperated Robotic Medical Devices
The U.S. Food and Drug Administration (FDA) published a discussion paper, Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities, and is asking stakeholders for feedback. The paper is not draft or final guidance and is meant to inform future policy. The FDA has not yet authorized any fully autonomous or teleoperated robotic device for the U.S. market. This is a policy and regulatory item with no active threat, vulnerability or exploitation. The article was the only source used; no web research was performed.
Detalhes técnicos
- Connected autonomous and teleoperated devices are cyber devices under Section 524B of the FD&C Act. Premarket cybersecurity requirements apply, including an SBOM, patch management and postmarket vulnerability monitoring and disclosure.
- The FDA says autonomy enlarges the threat surface. A compromise could affect a system's functionality, availability and data integrity.
- Risks are compounded when autonomy and remote teleoperation are combined.
- Sensor and imaging data integrity is a concern, for example a tampered video feed that users at either end cannot detect.
- The FDA favors an end-to-end system view. It expects strong authentication, integrity and non-repudiation controls so that commands can be confirmed as coming from authorized individuals.
- Availability must be maintained at both the control end and the procedural end.
Remediação
The FDA asks for comments on its 15 questions by January 5, 2027. A hybrid public workshop will be held on December 2-3, and registration closes on November 23, 2026.
Linha do tempo
-
FDA Seeks Public Feedback on Cybersecurity and Safety Risks of Autonomous and Remote Teleoperated Robotic Medical Devices
ler a análise desta fonte ocultar
The U.S. Food and Drug Administration (FDA) published a discussion paper, Evaluating Benefit-Risk in Robotic Medical Devices with Autonomous or Remote Teleoperation Capabilities, and is asking stakeholders for feedback. The paper is not draft or final guidance and is meant to inform future policy. The FDA has not yet authorized any fully autonomous or teleoperated robotic device for the U.S. market. This is a policy and regulatory item with no active threat, vulnerability or exploitation. The article was the only source used; no web research was performed.
Technical Details
- Connected autonomous and teleoperated devices are cyber devices under Section 524B of the FD&C Act. Premarket cybersecurity requirements apply, including an SBOM, patch management and postmarket vulnerability monitoring and disclosure.
- The FDA says autonomy enlarges the threat surface. A compromise could affect a system's functionality, availability and data integrity.
- Risks are compounded when autonomy and remote teleoperation are combined.
- Sensor and imaging data integrity is a concern, for example a tampered video feed that users at either end cannot detect.
- The FDA favors an end-to-end system view. It expects strong authentication, integrity and non-repudiation controls so that commands can be confirmed as coming from authorized individuals.
- Availability must be maintained at both the control end and the procedural end.
Remediation
The FDA asks for comments on its 15 questions by January 5, 2027. A hybrid public workshop will be held on December 2-3, and registration closes on November 23, 2026.